申请人:Sankyo Company, Limited
公开号:US05192766A1
公开(公告)日:1993-03-09
Compounds of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 is each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5, wherein R.sup.5 is optionally substituted aryl or aromatic heterocyclic; R.sup.3 is hydrogen, alkyl, cyano or --R.sup.5 ; X is oxygen or sulfur; A is 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B' is alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is optionally substituted phenyl and pharmaceutically acceptable salts thereof have valuable PAF antagonist activity, and may be prepared by reacting a compound containing the piperazine or homopiperazine part of the molecular with a compound containing the other part of the molecule.
式(I)的化合物:其中R.sup.1和R.sup.2分别为--R.sup.5,--CH.dbd.CH--R.sup.5或--C.tbd.C--R.sup.5,其中R.sup.5是可选择取代的芳基或芳香杂环基;R.sup.3是氢,烷基,氰基或--R.sup.5;X是氧或硫;A是1,4-哌嗪-1,4-二基或1,4-同源哌嗪-1,4-二基;B'是烷基,羰基,硫代羰基,砜基或磺酰基;R.sup.4是可选择取代的苯基和其药用盐具有有价值的PAF拮抗活性,可以通过将含有分子中哌嗪或同源哌嗪部分的化合物与含有分子的其他部分的化合物反应来制备。